Publicação
Molecular imaging agents for detection of β-amyloid plaques in Alzheimer’s disease
| Resumo: | The formation of amyloid structures is a neuropathological feature that characterizes several neurodegenerative disorders, such as Alzheimer´s and Parkinson´s disease. Up to now, the definitive diagnostic of these diseases can only be accomplished by immunostaining of post-mortem brain tissues with dyes such as Thioflavin T and congo red. Aiming at early in vivo diagnosis of Alzheimer´s disease (AD), several amyloid-avid radioprobes have been developed for β-amyloid imaging by positron emission tomography (PET) and single-photon emitted computed tomography (SPECT). The aim of this paper is to present a perspective of the available amyloid imaging agents, special those that have been selected for clinical trials and are at the different stages of US Food and Drugs Administration (FDA) approval. |
|---|---|
| Autores principais: | Quental, Letícia |
| Outros Autores: | Ribeiro Morais, Goreti; Santos, Isabel; Paulo, António |
| Assunto: | Doença de Alzheimer Agregação da β-amilóide Imagiologia molecular Sondas moleculares Alzheimer's disease β-Amyloid aggregation Molecular imaging Molecular probes |
| Ano: | 2013 |
| País: | Portugal |
| Tipo de documento: | artigo |
| Tipo de acesso: | unknown |
| Instituição associada: | Instituto Politécnico de Lisboa Escola Superior de Tecnologia da Saúde de Lisboa |
| Idioma: | inglês |
| Origem: | Saúde & Tecnologia |
| Resumo: | The formation of amyloid structures is a neuropathological feature that characterizes several neurodegenerative disorders, such as Alzheimer´s and Parkinson´s disease. Up to now, the definitive diagnostic of these diseases can only be accomplished by immunostaining of post-mortem brain tissues with dyes such as Thioflavin T and congo red. Aiming at early in vivo diagnosis of Alzheimer´s disease (AD), several amyloid-avid radioprobes have been developed for β-amyloid imaging by positron emission tomography (PET) and single-photon emitted computed tomography (SPECT). The aim of this paper is to present a perspective of the available amyloid imaging agents, special those that have been selected for clinical trials and are at the different stages of US Food and Drugs Administration (FDA) approval. |
|---|